Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Propofol 6Carboplatin 5Sevoflurane 4Saline Solution 3Paclitaxel 3Nivolumab 3Erlotinib Hydrochloride 3Acetaminophen 3Pemetrexed 2Midazolam 2Lidocaine 2Isoflurane 2Docetaxel 2Desflurane 2Cryotherapy 2Bupivacaine 2Bronchoscopy 2Anesthesia, Inhalation 2trametinib 1sotorasib 1pegfilgrastim 1icotinib 1endostar protein 1durvalumab 1dabrafenib 1capmatinib 1camrelizumab 1beta Carotene 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lung Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

Phase 4 Recruiting
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡